We will know, based on price movement, which outcome is more likely. I can't for the life of me understand why there are no insider buys at this price- I mean 'BIG BUYS'! I do not think we are getting bought out like one of the posters mentioned, so what the hell is preventing them from stepping up to the plate and buying shares?
The difference is the guy buying into the company has a great track record, so the push is on the basis that this company is going to come out with something special w/ him at the helm. On the flip side, we have a CEO in Hobbs that had run a company that went downhill under his watch. So, we will not get the benefit of the doubt. We need to sell injectors on lucrative products- such as EPI- get SUMA approved and/or increase sales in Otrexup fast before the money runs down to 20 mil again.
Now that is a long talking.. I remember feeling the way we do when I first purchased KERX and ACAD and ended up selling them way to early at the time. I've decided ATRS is my long term hold and will not sell under $10 plus. When we finally get there I will assess to see if I should sell or continue to hold.
Sentiment: Strong Buy
I guess the person who decided to fund KBIO feels this company may find the cure for cancer. We don't have anything nearly as powerful as the cure for cancer, only 'shells' that we need for companies like TEVA to use for a number of the specialty generics it has coming. Also, for Otrexup and QST- proprietary products- to add to growth. We could be a 15-30 stock one day in the not to distant future but we need a little luck on our side which we have not had. In fact, we have had the opposite but look at KBIO. Life can change in a matter of days, timing is everything!
Good news keeps coming... ""The submission was among a select group of key abstracts awarded the distinction of a moderated poster presentation""
EWING, N.J., Nov. 20, 2015 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (ATRS) today announced that data from its Phase 3 study of the pharmacokinetics and safety of subcutaneous testosterone enanthate delivered through the QuickShot® auto injector was selected for a moderated poster presentation on November 21, 2015 at the 21st Annual Fall Scientific Meeting of the Sexual Medicine Society of North America.
The poster, entitled “Testosterone enanthate administered once-weekly by subcutaneous auto-injector in men with hypogonadism: pharmacokinetic and safety results from a phase III trial,” was authored by Jed C. Kaminetsky, MD, Manhattan Medical Research, University Urology, New York, NY, et al. The submission was among a select group of key abstracts awarded the distinction of a moderated poster presentation.
Sentiment: Strong Buy
Unfortunately people commit suicide and in all probability there was more going on with this person than low testosterone. It may have been an ATRS shareholder that bought at 5.00 who knows.
The suicide was interesting, The guy actually stood on the injector and leaped to his death. He was wearing Nike running shoes. Due to this unfortunate event all Antares injectors and all Nike footwear will be banned.
"To date, three serious adverse events including one case each of depression, suicide and vertigo were recorded, with no major cardiac events reported in the study. "